•Report: Rural residents face steep gap in retina care access•Leadership watch: LENZ, CooperCompanies CEOs step down, among exec changes•Roivant, Priovant report positive phase 3 NIU data for brepocitinib•Industry payments tied to higher prescribing volume, costs•FDA approves Xbrane Biopharma's Lucentis biosimilar•Report: Rural residents face steep gap in retina care access•Leadership watch: LENZ, CooperCompanies CEOs step down, among exec changes•Roivant, Priovant report positive phase 3 NIU data for brepocitinib•Industry payments tied to higher prescribing volume, costs•FDA approves Xbrane Biopharma's Lucentis biosimilar
HEADLINES
FEATURED
Oral small molecule is designed to correct protein misfolding for RHO gene mutations, the root cause of RHO-adRP; phase 1/2 clinical study currently underway.
Earn FREE CE 24/7 with Courses by Eyes On Eyecare
Explore premium-quality, bite-sized courses featuring leading experts like Cecelia Koetting, OD, FAAO, and Cory Lappin, OD, MS, FAAO, and continuing education covering topics from ocular rosacea treatments to retinal disease.
